LT3519394T - Kalkobutrolio modifikacijos kristalinės formos gavimo būdas - Google Patents

Kalkobutrolio modifikacijos kristalinės formos gavimo būdas

Info

Publication number
LT3519394T
LT3519394T LTEP17768733.2T LT17768733T LT3519394T LT 3519394 T LT3519394 T LT 3519394T LT 17768733 T LT17768733 T LT 17768733T LT 3519394 T LT3519394 T LT 3519394T
Authority
LT
Lithuania
Prior art keywords
calcobutrol
modification
obtaining
crystalline form
crystalline
Prior art date
Application number
LTEP17768733.2T
Other languages
English (en)
Inventor
Johannes Platzek
Wilhelm Trentmann
Original Assignee
Bayer Pharma Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma Aktiengesellschaft filed Critical Bayer Pharma Aktiengesellschaft
Publication of LT3519394T publication Critical patent/LT3519394T/lt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F3/00Compounds containing elements of Groups 2 or 12 of the Periodic Table
    • C07F3/04Calcium compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/06Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10Organic compounds
    • A61K49/101Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/106Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA
    • A61K49/108Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA the metal complex being Gd-DOTA
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D257/00Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Radiology & Medical Imaging (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
LTEP17768733.2T 2016-09-27 2017-09-11 Kalkobutrolio modifikacijos kristalinės formos gavimo būdas LT3519394T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16190812 2016-09-27
PCT/EP2017/072683 WO2018059914A1 (en) 2016-09-27 2017-09-11 Method for producing the crystalline form of modification a of calcobutrol

Publications (1)

Publication Number Publication Date
LT3519394T true LT3519394T (lt) 2020-09-25

Family

ID=57003447

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP17768733.2T LT3519394T (lt) 2016-09-27 2017-09-11 Kalkobutrolio modifikacijos kristalinės formos gavimo būdas

Country Status (26)

Country Link
US (2) US10793532B2 (lt)
EP (1) EP3519394B1 (lt)
JP (2) JP7053590B2 (lt)
KR (1) KR102395523B1 (lt)
CN (1) CN109803958B (lt)
AR (1) AR109729A1 (lt)
AU (1) AU2017333698B2 (lt)
BR (1) BR112019006066A2 (lt)
CA (1) CA3038036C (lt)
CY (1) CY1123317T1 (lt)
DK (1) DK3519394T3 (lt)
ES (1) ES2809736T3 (lt)
HR (1) HRP20200922T1 (lt)
HU (1) HUE050553T2 (lt)
IL (1) IL265536B (lt)
LT (1) LT3519394T (lt)
MX (1) MX382574B (lt)
NZ (1) NZ751256A (lt)
PL (1) PL3519394T3 (lt)
PT (1) PT3519394T (lt)
RS (1) RS60392B1 (lt)
SG (1) SG11201901460UA (lt)
SI (1) SI3519394T1 (lt)
TW (1) TWI765913B (lt)
UY (1) UY37421A (lt)
WO (1) WO2018059914A1 (lt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10793532B2 (en) * 2016-09-27 2020-10-06 Bayer Pharma Aktiengesellschaft Method for producing the crystalline form of modification a of calcobutrol
WO2020012372A1 (en) * 2018-07-10 2020-01-16 Biophore India Pharmaceuticals Pvt. Ltd Process for the preparation of 2,2',2''-(10-((2r,3s)-1,3,4-trihydroxy butan-2-yl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl) triacetic acid and its complexes
WO2020084504A1 (en) * 2018-10-24 2020-04-30 Biophore India Pharmaceuticals Pvt. Ltd Novel process for the preparation of macrocyclic chelant 2,2',2''-(10-(2-hydroxypropyl)-1,4,7,10-tetra azacyclododecane-1,4,7-triyl) triacetic acid and it's complexes with paramagnetic metal ions
CN111039885B (zh) * 2019-12-06 2021-03-05 广州康瑞泰药业有限公司 一种制备高纯度考布曲钙的方法
KR20210112910A (ko) * 2020-03-06 2021-09-15 주식회사 엔지켐생명과학 가도부트롤 주사제 제조를 위한 부형제인 칼코부트롤의 제조 방법
KR20210114742A (ko) * 2020-03-11 2021-09-24 주식회사 엔지켐생명과학 칼테리돌의 제조방법
CN114573522A (zh) * 2020-11-30 2022-06-03 江苏恒瑞医药股份有限公司 一种考布曲钙的新晶型及其制备方法
CN119143689B (zh) * 2024-11-15 2025-05-30 苏州美诺医药科技有限公司 考布曲钙和其中间体的制备方法

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1491129A (en) 1975-06-04 1977-11-09 Guerbet Sa Iodo-benzene derivatives and an x-ray contrast medium containing them
US4284620A (en) 1979-03-23 1981-08-18 Mallinckrodt, Inc. N-(2-Hydroxyethyl)-2,4,6-triiodo-3,5-bis-(2-keto-L-gulonamido)benzamide and radiological compositions containing same
NO161560C (no) 1980-04-17 1989-09-06 Univ California Symmetriske trijodisoftaldiamid-derivater og roentgenkontrastmidler inneholdende disse.
DE3150916A1 (de) 1981-12-18 1983-06-30 Schering Ag, 1000 Berlin Und 4619 Bergkamen N-hydroxyaethylierte 2,4,6-trijodaminoisiophthalsaeure-bis- trihydroxybutylamide, deren herstellung und diese enthaltende roentgenkontrastmittel"
US5064633A (en) 1984-06-04 1991-11-12 The Dow Chemical Company Macrocyclic aminophosphonic acid complexes, their formulations and use
US5059412A (en) 1984-06-04 1991-10-22 The Dow Chemical Company Macrocyclic aminophosphonic acid complexes for the treatment of calcific tumors
MX174467B (es) 1986-01-23 1994-05-17 Squibb & Sons Inc 1,4,7-triscarboximetil-1,4,7,10-tetraazaciclodo decano substituido en 1 y compuestos analogos
US4885363A (en) 1987-04-24 1989-12-05 E. R. Squibb & Sons, Inc. 1-substituted-1,4,7-triscarboxymethyl-1,4,7,10-tetraazacyclododecane and analogs
DE3625417C2 (de) 1986-07-28 1998-10-08 Schering Ag Tetraazacyclododecan-Derivate
DE3640708C2 (de) 1986-11-28 1995-05-18 Schering Ag Verbesserte metallhaltige Pharmazeutika
DE4009119A1 (de) 1990-03-19 1991-09-26 Schering Ag 1,4,7,10-tetraazacyclododecan-butyltriole, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische mittel
IE910955A1 (en) 1990-03-23 1991-09-25 Yamanouchi Europ Bv Il-6 inhibiting compositions
DE4035760A1 (de) 1990-11-08 1992-05-14 Schering Ag Mono-n-substituierte 1,4,7,10-tetraazacyclododecan-derivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische mittel
US5410043A (en) 1991-12-06 1995-04-25 Schering Aktiengesellschaft Process for the production of mono-N-substituted tetraaza macrocycles
DE4237943C2 (de) 1992-11-06 1997-10-23 Schering Ag Verfahren zur Herstellung von Metallkomplexen der N-beta-Hydroxyalkyl-tri-N-carboxyalkyl-1,4,7,10-tetraazacyclododecan- und N-beta-Hydroxyalkyl-tri-N-carboxyalkyl-1,4,8,11-tetraazacyclotetradecan-Derivate
DE4218744C2 (de) 1992-06-04 1997-11-06 Schering Ag Verfahren zur Herstellung von N-ß-Hxdroxyalkyl-tri-N-carboxylalkyl-1,4,7,10-tetraazacyclododecan- und N-ß-Hydroxyalkyl-tri-N-carboxyalkyl-1,4,8,11-tetraazacyclotetradecan-Derivaten und deren Metallkomplexe
DE4318369C1 (de) 1993-05-28 1995-02-09 Schering Ag Verwendung von makrocyclischen Metallkomplexen als Temperatursonden
US5358704A (en) 1993-09-30 1994-10-25 Bristol-Myers Squibb Hepatobiliary tetraazamacrocyclic magnetic resonance contrast agents
IT1275426B (it) 1995-05-16 1997-08-07 Bracco Spa Recupero del gadolinio e dei suoi agenti complessanti da soluzioni acquose contenenti i loro complessi
DE19724186C2 (de) 1997-06-02 2002-07-18 Schering Ag Verfahren zur Mono- und 1,7-Bis-N-ß-Hydroxyalkylierung von Cyclen und die entsprechenden N-ß-Hydroxyalkyl-1,4,7,10-tetraazacyclododecan-Li-Salz-Komplexe
US9016221B2 (en) 2004-02-17 2015-04-28 University Of Florida Research Foundation, Inc. Surface topographies for non-toxic bioadhesion control
DE102009053171B4 (de) * 2009-11-04 2011-07-21 Bayer Schering Pharma Aktiengesellschaft, 13353 Verfahren zur Herstellung des Calcium-Komplexes von Dihydroxy-hydroxy-methylpropyl-tetraazacyclododecan-triessigsäure (Calcobutrol)
KR20200059319A (ko) * 2011-04-21 2020-05-28 바이엘 인텔렉쳐 프로퍼티 게엠베하 고순도 가도부트롤의 제조
WO2012170676A1 (en) * 2011-06-08 2012-12-13 Sti Pharma, Llc Controlled absorption water-soluble pharmaceutically active organic compound formulation for once-daily administration
KR101693400B1 (ko) 2014-09-17 2017-01-05 에스티팜 주식회사 칼코부트롤의 제조방법
CN105037288B (zh) * 2015-07-23 2017-11-03 上海现代制药海门有限公司 一种布醇的制备方法
CN106187930B (zh) * 2016-07-12 2018-10-19 嘉实(湖南)医药科技有限公司 高纯度考布曲钙的制备方法
US10793532B2 (en) * 2016-09-27 2020-10-06 Bayer Pharma Aktiengesellschaft Method for producing the crystalline form of modification a of calcobutrol

Also Published As

Publication number Publication date
CA3038036C (en) 2024-01-23
IL265536A (en) 2019-05-30
JP2019534869A (ja) 2019-12-05
ES2809736T3 (es) 2021-03-05
JP2022071132A (ja) 2022-05-13
CY1123317T1 (el) 2021-12-31
AU2017333698B2 (en) 2020-12-24
AR109729A1 (es) 2019-01-16
PL3519394T3 (pl) 2020-11-30
JP7053590B2 (ja) 2022-04-12
TWI765913B (zh) 2022-06-01
RS60392B1 (sr) 2020-07-31
PT3519394T (pt) 2020-08-03
EP3519394B1 (en) 2020-05-27
SI3519394T1 (sl) 2020-08-31
AU2017333698A1 (en) 2019-03-07
HRP20200922T1 (hr) 2020-09-18
HUE050553T2 (hu) 2020-12-28
TW201815771A (zh) 2018-05-01
US10793532B2 (en) 2020-10-06
RU2019111919A (ru) 2020-10-29
MX2019003540A (es) 2019-08-14
UY37421A (es) 2018-01-31
IL265536B (en) 2022-07-01
BR112019006066A2 (pt) 2019-06-18
SG11201901460UA (en) 2019-03-28
CN109803958A (zh) 2019-05-24
CA3038036A1 (en) 2018-04-05
US20190210979A1 (en) 2019-07-11
MX382574B (es) 2025-03-13
WO2018059914A1 (en) 2018-04-05
EP3519394A1 (en) 2019-08-07
DK3519394T3 (da) 2020-08-17
CN109803958B (zh) 2023-10-31
KR102395523B1 (ko) 2022-05-10
US20210009534A1 (en) 2021-01-14
JP7444914B2 (ja) 2024-03-06
US11390592B2 (en) 2022-07-19
NZ751256A (en) 2020-05-29
RU2019111919A3 (lt) 2020-12-28
KR20190040064A (ko) 2019-04-16

Similar Documents

Publication Publication Date Title
IL268852A (en) Crystalline forms of the 4-pyrimidinesulfamide derivative aprocitentan
LT3191461T (lt) 6-karboksi-2-(3,5-dichlorfenil)-benzoksazolo kristalinės kietos formos
LT3472157T (lt) Kristalinės kietos bet inhibitoriaus formos
PL3481942T3 (pl) Sposoby hodowania organoidów
PL3325443T3 (pl) Sposób otrzymywania pridopidyny
PT3368534T (pt) Ditosilato de valbenazina e polimorfos do mesmo
IL264143B (en) Processes for preparing olaparib
EP3420388A4 (en) PUPILS EQUALIZATION
BR112016020830A2 (pt) composição de poliolefina heterofásica modificada e método de preparação
LT3565542T (lt) Polimorfinės rad1901-2hcl formos
LT3519394T (lt) Kalkobutrolio modifikacijos kristalinės formos gavimo būdas
IL272851A (en) Methods of using dipivefrin
LT3490988T (lt) Naujas junginys ir gavimo būdas
PL3630738T3 (pl) Sposób wytwarzania ozanimodu
BR112016025413A2 (pt) método de fabricação de um inserto e inserto
HUE049170T2 (hu) Eljárás szubsztituált cikloszerinek elõállítására
IL313083A (en) Terlipressin compositions and their methods of use
LT3191475T (lt) 6-((6, 7-dimetoksichinazolin-4-il)oksi) -n,2-dimetilbenzofuran-3-karboksamido kristalinės formos
DK3653599T3 (da) Krystallinsk tapentadolphosphat
IL284374A (en) Methods of producing ustekinumab
SI3529236T1 (sl) Kristalinične oblike eravaciklina
PL3717523T3 (pl) Sposób modyfikacji ldpe
EP3532637A4 (en) DETECTION PROCESS
LT3327012T (lt) Bilastino kristalinės formos ir jų gamybos būdai
IL263526A (en) Solid state forms of ixazomib citrate